$NRXS

Neuraxis, INC (NRXS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (e) Compensatory Arrangements of Certain Officers Stock Option Exchange As previously disclosed, on June 10, 2026, the stock

NeurAxis (NRXS) shares fell after Q2 2026 results for the quarter ended June 30. Revenue rose to $1.9M, up 115.7% year over year, and loss per share narrowed to $0.19. Net loss and operating loss widened to $2.1M each. Gross margin increased to 85.9% from 83.6% as average selling price rose 28% to $992. Cash was $8.3M.

NeurAxis (NRXS) reported Q2 2026 revenue of $1.928 million, up 116% year over year, driven by increased payer and reimbursement coverage, with IB-Stim ASP rising to $992 per device (+28%). Gross margin was 85.9%. Operating loss was $2.1 million and net loss $2.1 million. Cash on hand was $8.3 million as of June 30, 2026.

NeurAxis (NYSE American: NRXS) reported Q2 2026 revenue of $1.9M, up 116% year over year, citing PENFS Category I CPT code coverage effective Jan. 1, 2026. Gross margin rose to 85.9%. Cash was $8.3M at June 30, 2026. The company also cited VA FSS contract and FDA clearance for functional dyspepsia abdominal pain.

Neuraxis, INC (NRXS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan (As Amended As of June 11, 2026) Table of Contents Page ARTICLE I PURPOSE 1 ARTICLE II DEFINITIONS 1 ARTICLE III EFFECTIVE DATE OF PLAN 6 ARTICLE IV ADMINISTRATION 6 Section 4.1 Ad

Neuraxis Inc has announced its net sales expectations for the three months ending March 31, 2026. The company anticipates achieving approximately $1.6 million in net sales during this period. This news was reported by Reuters.

NeurAxis posts its fifth straight quarter of double-digit expansion, but rising costs and margin pressure weigh on third-quarter 2025 results.

CARMEL, Ind., Nov. 12, 2025 ( GLOBE NEWSWIRE ) -- NeurAxis, Inc. ( "NeurAxis" or the "Company" ) ( NYSE:NRXS ) , a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced new medical policy coverage for ...

Achieves significant expansion of NeurAxis' total addressable market Clearance now includes patients aged "8 years and older" Expanded age indication will utilize the upcoming January 1st, 2026, Category I CPT code to report PENFS procedures

CARMEL, Ind., June 17, 2025 ( GLOBE NEWSWIRE ) -- NeurAxis, Inc. ( "NeurAxis," or the "Company" ) ( NYSE American: NRXS ) , a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy ...